Correction - Updated version 1 - Quarterly profit of natural gas producer Expand Energy exceeds market expectations
路透社2026/10/27 20:57Correction: Added the missing word "per share" in paragraph 5
Reuters, October 27 - Expand Energy (EXE.O), the largest natural gas producer in the United States, reported third-quarter profits on Tuesday that exceeded Wall Street expectations, mainly due to increased natural gas production.
Driven by liquefied natural gas (LNG) exports and power demand from artificial intelligence data centers, U.S. natural gas consumption is expected to reach a new historic high.
The stock rose 1.5% in after-hours trading.
For the quarter ended September 30, the company's average daily natural gas output was approximately 7.54 billion cubic feet equivalent, up from about 7.33 billion cubic feet equivalent a year earlier.
According to data compiled by London Stock Exchange Group (LSEG), the company’s adjusted earnings per share for the quarter ended September 30 were $1.46, while analysts’ average expectation was per share $1.27.
(To assist those who are not native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it only for convenience. Reuters assumes no responsibility for any damage or loss resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
